Verlaufskontrolle nach IVOM-Therapie bei diabetischem Makulaödem

Ziel dieses Beitrages ist, dem Leser einen Leitfaden für eine strukturierte Untersuchung bei Patienten mit diabetischem Makulaödem bei der Kontrolle während oder nach der IVOM-Therapie zu geben. Ein Schwerpunkt liegt dabei auf der OCT-basierten Therapieentscheidung.

• Literatur

• 1 Wild PS, Pfeiffer N, Mirshahi A. et al. Prevalence and Cardiovascular Associations of Diabetic Retinopathy and Maculopathy: Results from the Gutenberg Health Study. PLoS One 2015; 10: e0139527 doi:10.1371/journal.pone.0139527
• 2 Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study research group. Arch Ophthalmol 1985; 103: 1796-1806
• 3 Frank RN. Etiologic Mechanisms in Diabetic Retinopathy. Retina 2005; 2: 1241-1270 doi:10.1016/B978-0-323-02598-0.50072-0
• 4 Duker JS, Waheed NK, Goldmann DR. Handbook of retinal OCT: Optical Coherence Tomography. London, New York, Oxford, Philadelphia, St Louis, Sydney, Toronto: Elsevier Saunders; 2014
• 5 Sarangi R, Silva PS, Aiello LP. Disorganization of the Retinal Inner Layers as a Predictor of Visual Acuity in Eyes With Center-Involved Diabetic Macular Edema. JAMA Ophthalmol 2014; 132: 1309-1316
• 6 Bolz M, Schmidt-Erfurth U, Deak G. et al. Optical coherence tomographic hyperreflective foci: a morphologic sign of lipid extravasation in diabetic macular edema. Ophthalmology 2009; 116: 914-920 doi:10.1016/j.ophtha.2008.12.039
• 7 Framme C, Schweizer P, Imesch M. et al. Behavior of SD-OCT-detected hyperreflective foci in the retina of anti-VEGF-treated patients with diabetic macular edema. Invest Ophthalmol Vis Sci 2012; 53: 5814-5818 doi:10.1167/iovs.12-9950
• 8 Ota M, Nishijima K, Sakamoto A. et al. Optical coherence tomographic evaluation of foveal hard exudates in patients with diabetic maculopathy accompanying macular detachment. Ophthalmology 2010; 117: 1996-2002
• 9 Framme C, Wolf S, Wolf-Schnurrbusch U. Small dense particles in the retina observable by spectraldomain optical coherence tomography in age-related macular degeneration. Invest Ophthalmol Vis Sci 2010; 51: 5965-5969 doi:10.1167/iovs.10-5779
• 10 Coscas G, De Benedetto U. Coscas Fet al. Hyperreflective dots: a new spectral-domain optical coherence tomography entity for follow-up and prognosis in exudative age-related macular degeneration. Ophthalmologica 2013; 229: 32-37
• 11 Uji A, Murakami T, Nishijima K. et al. Association between hyperreflective foci in the outer retina, status of photoreceptor layer, and visual acuity in diabetic macular edema. Am J Ophthalmol 2012; 153: 710-717
• 12 Schreur V, Altay L, van Asten F. et al. Hyperreflective foci on optical coherence tomography associate with treatment outcome for anti-VEGF in patients with diabetic macular edema. PLoS One 2018; 13: e0206482 doi:10.1371/journal.pone.0206482
• 13 Campos A, Campos EJ, do Carmo A. et al. Evaluation of markers of outcome in real-world treatment of diabetic macular edema. Eye Vis (Lond) 2018;
• 14 Regatieri CV, Brannchini L, Carmody J. et al. Choroidal thickness in patients with diabetic retinopathy analyzed by spectral-domain optical coherence tomography. Retina 2012; 32: 563-568
• 15 Manjunath V, Taha M, Fujimoto JG. et al. Choroidal thickness in normal eyes measured using Cirrus HD optical coherence tomography. Am J Ophthalmol 2010; 150: 325-329.e1
• 16 DRCR.NET. Protocol I – Macular Laser Combined with Ranibizumab or Triamcinalone vs. Macular Laser Alone. Am J Ophthalmol 2016; 164: 57-68
• 17 DRCR.NET. Protocol T-Aflibercept, Bevacizumab or Ranibizumab for Diabetic Macular Edema. N Engl J Med 2015; 372: 1193
• 18 DRCR.NET. Protocol S – Panretinal Photocoagulation vs. lntravitreal Ranibizumab for Proliferative Diabetic Retinopathy. JAMA 2015; 314: 2137-2146
• 19 Nguyen QD, Brown DM, Marcus DM. et al. Ranibizumab for diabetic macular edema, results from 2 phase III randomized trials: RISE und RIDE. J Ophtha 2012; 119: 789-801
• 20 Heier JS, Korobelnik JF, Brown DM. et al. Intravitreal Aflibercept for Diabetic Macular Edema: 148-Week Results from the VISTA and VIVID Studies. Ophthalmology 2016; 123: 2376-2385 doi:10.1016/j.ophtha.2016.07.032
• 21 Rajendram R, Fraser-Bell S, Kaines A. et al. A 2-year prospective randomized controlled trial of intravitreal bevacizumab or laser therapy (BOLT) in the management of diabetic macular edema: 24-month data. Arch Ophthalmol 2012; 130: 972-979
• 22 Pacella F, Romano MR, Turchetti P. et al. An eighteen-month follow-up study on the effects of Intravitreal Dexamethasone Implant in diabetic macular edema refractory to anti-VEGF therapy. Int J Ophthalmol 2016; 9: 1427-1432
• 23 Nentwich MM, Lemmen KD, Ulbig MW. Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulaopathie. Z Prakt Augenheilkd 2010; 31: 491-499